Table 2. Comparison of thrombosis... | American Society of Hematology

Table 2.

Comparison of thrombosis recurrence/risk reduction and bleeding risk in key studies of comparing VKAs and DOACs in secondary prevention after PV/MPN-related VTE^*

Choice of AC	Overall recurrence	VKA (N = number treated)	DOAC	P value	VKA+CR	DOAC + CR	P value	Bleeding events on VKA	Bleeding events on DOAC	p-value
Hamulyak et al¹² Systematic Review N = 1295 patients	22.6%	36.8% (N = 106)	21.4% (N = 14)	N/R	17.6% (N = 313)	7.9% (N = 63)	N/R	N/R	8 events	N/R
Huenerbein et al¹³ Retrospective Review N = 71	8.0% per py	84.6%^**, δ (N = 45)	4%^** (N = 26)	0.0003	(N = 22)	(N = 17)	N/R	63.6%	36.4%	0.516
Fedorov et al¹⁴ Retrospective Review N = 30	6.7%	9.1%^** (N = 11)	5.3%^** (N = 19)	1.0				21.1%	9.1%	0.63

Choice of AC	Overall recurrence	VKA (N = number treated)	DOAC	P value	VKA+CR	DOAC + CR	P value	Bleeding events on VKA	Bleeding events on DOAC	p-value
Hamulyak et al¹² Systematic Review N = 1295 patients	22.6%	36.8% (N = 106)	21.4% (N = 14)	N/R	17.6% (N = 313)	7.9% (N = 63)	N/R	N/R	8 events	N/R
Huenerbein et al¹³ Retrospective Review N = 71	8.0% per py	84.6%^**, δ (N = 45)	4%^** (N = 26)	0.0003	(N = 22)	(N = 17)	N/R	63.6%	36.4%	0.516
Fedorov et al¹⁴ Retrospective Review N = 30	6.7%	9.1%^** (N = 11)	5.3%^** (N = 19)	1.0				21.1%	9.1%	0.63

Studies included both arterial and venous events as recurrences.

^**

Includes patients treated with and without CR and with or without aspirin.

^δ

Includes recurrences both on and after stopping AC therapy.

CR, cytoreduction; py, patient-year.

View Large

This Feature Is Available To Subscribers Only